Sarcomatoid renal cell carcinoma (RCC) is difficult to treat and has long been associated with a poor prognosis. Also, the biology of sarcomatoid RCC has remained obscure. Scientists have tried to determine the molecular profile of sarcomatoid RCC and investigate different targeted therapies for genes such as TP53, BAP1, cell cycle, and chromatin-remodelling genes. Investigation of […]
The past decade or so has seen the development of multiple targeted therapies for metastatic renal cell carcinoma (RCC), such as vascular endothelial growth factor (VEGF) inhibitors and inhibitors of the mammalian target of rapamycin (mTOR) pathway. Most recently, immune checkpoint inhibitors have been shown to have excellent clinical efficacy. Although patients are living longer, […]
Most renal cell carcinomas (RCC) are diagnosed from studying the cells from a biopsy under a microscope (histology findings), with and without the use of antibodies to check for certain proteins in the tumour tissue (immunohistochemical examination). RCC tumours are very heterogeneous – there are many subtypes of RCC which have different appearances under the […]
A recent review of the use of immune checkpoint inhibitors for the treatment of metastatic renal cell carcinoma (RCC) was published in European Urology Focus this month. The use of immune checkpoint inhibitors has revolutionised the treatment of metastatic RCC over recent years. However, the appropriate duration of treatment with immune checkpoint inhibitors, such as […]
A study published in the Journal of Vascular and Interventional Radiology looked at the long-term survival benefits from radiofrequency ablation (RFA) in patients with localised renal cell carcinoma (RCC). The outcomes of 100 patients with localised RCC (kidney cancer that has not spread) were looked at retrospectively. All patients had percutaneous radiofrequency ablation and were […]
In 2015, the standard treatment for most patients with advanced kidney cancer was a vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) such as sunitinib or pazopanib for untreated patients, followed by a checkpoint inhibitor (PD-1 inhibitor) such as nivolumab for patients who fail treatment with a VEGF inhibitor. However, over the last several […]
Over the past couple of years there have been several approvals of new treatments and drug combinations for advanced/metastatic renal cell carcinoma (RCC) resulting in treatment plans that are tailored for the individual patient. Recent advances in the treatment of advanced/metastatic RCC include cabozantinib, nivolumab/ipilimumab, pembrolizumab/axitinib and avelumab/axitinib. Dr Ajjai Shivaram Alva, associate professor at […]
Immune checkpoint inhibitors (ICIs), such as nivolumab and ipilimumab have revolutionised the treatment for metastatic renal cell carcinoma (RCC). However, the most appropriate duration for immunotherapy treatment is not clear. In a recent analysis of the results from the phase III CheckMate 214 trial, all RCC patients randomised to receive the nivolumab/ipilimumab combination had longer […]
In this interview with OncLive, Dr Ulka Vaishampayan from Wayne State University in Detroit, USA discusses the immunotherapy combinations that have been approved for first line treatment of metastatic renal cell carcinoma (mRCC) over the past year or so, and the need to identify biomarkers that can guide treatment selection for these patients. The combination […]
In this interview with OncLive, professor Sumanta Kumar Pal from City of Hope Hospital in California discusses the potential of poly ADP ribose polymerase (PARP) inhibitors, chimeric antigen receptor (CAR)-based products, vaccines, and novel drug combinations for the treatment of metastatic renal cell carcinoma (mRCC). Results from the phase Ib/II TiNivo study of the combination […]
Copyright 2017 Kidney Cancer Support Network- Douglass Digital | Cambridge Web Design
